Janero D R, Burghardt B, Lopez R
Department of Pharmacology and Chemotherapy, Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110.
Biochem Pharmacol. 1988 Nov 1;37(21):4197-203. doi: 10.1016/0006-2952(88)90116-5.
Calcium antagonists representative of the four major chemical classes were assessed for their abilities to prevent peroxidation of rat heart membrane lipids through xanthine oxidase-dependent, superoxide-driven, iron-promoted oxygen radical chemistry. The dihydropyridines nifedipine and nitrendipine did not affect peroxidation, even at a concentration (500 microM) approaching their solubility limit. The benzothiazepine diltiazem did protect the cardiac lipids against oxidative injury, but at high micromolar concentrations: 50% inhibition of peroxidation (antiperoxidant IC50) required 510 microM diltiazem. The phenylalkylamines verapamil and gallopamil (D-600) were likewise weak antiperoxidants (approximately 35% inhibition of peroxidation at 500 microM). In contrast, two other alkylamines, bepridil and prenylamine, were very effective membrane lipid protectants with respective antiperoxidant IC50 values of 55 and 75 microM. The diphenylpiperazines flunarizine (IC50 = 190 microM) and cinnarizine (IC50 = 180 microM) displayed moderate antiperoxidant activity. No Ca2+ antagonist inhibited xanthine oxidase under conditions whereby 10 microM allopurinol inhibited enzyme activity by 50%. The effects of the Ca2+ antagonist-antiperoxidants on the kinetics of cardiac membrane lipid peroxidation indicate that they inhibit peroxidation by intercepting oxy- and/or lipid free radical intermediates. These data raise the possibility that antiperoxidant action may contribute to the spectrum of pharmacologic and therapeutic activities of certain Ca2+ antagonists.
对代表四大化学类别的钙拮抗剂进行了评估,以测定它们通过黄嘌呤氧化酶依赖性、超氧化物驱动、铁促进的氧自由基化学作用来预防大鼠心脏膜脂质过氧化的能力。二氢吡啶类的硝苯地平和尼群地平即使在接近其溶解度极限的浓度(500微摩尔)下也不影响过氧化作用。苯并硫氮䓬类的地尔硫䓬确实能保护心脏脂质免受氧化损伤,但需要高微摩尔浓度:抑制50%的过氧化作用(抗氧化剂IC50)需要510微摩尔的地尔硫䓬。苯烷基胺类的维拉帕米和加洛帕米(D - 600)同样是弱抗氧化剂(在500微摩尔时约35%抑制过氧化作用)。相比之下,另外两种烷基胺类药物苄普地尔和普尼拉明是非常有效的膜脂质保护剂,其抗氧化剂IC50值分别为55和75微摩尔。二苯基哌嗪类的氟桂利嗪(IC50 = 190微摩尔)和桂利嗪(IC50 = 180微摩尔)表现出中等的抗氧化活性。在10微摩尔别嘌呤醇抑制酶活性50%的条件下,没有钙拮抗剂能抑制黄嘌呤氧化酶。钙拮抗剂抗氧化剂对心脏膜脂质过氧化动力学的影响表明,它们通过拦截氧自由基和/或脂质自由基中间体来抑制过氧化作用。这些数据增加了一种可能性,即抗氧化作用可能有助于某些钙拮抗剂的药理和治疗活性谱。